[Federal Register Volume 69, Number 209 (Friday, October 29, 2004)]
[Notices]
[Page 63178]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 04-24154]


-----------------------------------------------------------------------

DEPARTMENT OF JUSTICE

Drug Enforcement Administration


Manufacturer of Controlled Substances; Notice of Application

    Pursuant to 21 CFR 1301.33(a), this is notice that on May 25, 2004, 
Cambrex North Brunswick Inc., Technology Centre of New Jersey, 661 
Highway One, North Brunswick, New Jersey 08902, made application by 
renewal and on June 11, 2004 by letter to the Drug Enforcement 
Administration (DEA) for registration as a bulk manufacturer of the 
basic classes of controlled substances listed:

------------------------------------------------------------------------
                    Drug                               Schedule
------------------------------------------------------------------------
N-Ethylamphetamine (1475)..................  I
Tetrahydrocannabinols (7370)...............  I
2,5-Dimethoxyamphetamine (7396)............  I
3,4-Methylenedioxyamphetamine (7400).......  I
4-Methoxyamphetamine (7411)................  I
Amphetamine (1100).........................  II
Methamphetamine (1105).....................  II
Methylphenidate (1724).....................  II
Codeine (9050).............................  II
Hydromorphone (9150).......................  II
Hydrocodone (9193).........................  II
Methadone (9250)...........................  II
Methadone Intermediate (9254)..............  II
Morphine (9300)............................  II
Sufentanil (9740)..........................  II
Fentanyl (9801)............................  II
------------------------------------------------------------------------

    The company plans to manufacture the listed controlled substances 
in bulk for distribution to its customers.
    Any other such applicant and any person who is presently registered 
with DEA to manufacture such a substance may file comments or 
objections to the issuance of the proposed registration pursuant to 21 
CFR 1301.33(a).
    Any such comments or objections may be addressed, in quintuplicate, 
to the Deputy Assistant Administrator, Office of Diversion Control, 
Drug Enforcement Administration, United States Department of Justice, 
Washington, DC 20537, Attention: DEA Federal Register Representative 
(ODLR) and must be filed no later than December 28, 2004.

    Dated: October 1, 2004.
William J. Walker,
Deputy Assistant Administrator, Office of Diversion Control, Drug 
Enforcement Administration.
[FR Doc. 04-24154 Filed 10-28-04; 8:45 am]
BILLING CODE 4410-09-P